RG1 antibodies and uses thereof
AssigneeBayer Schering Pharma Aktiengesellschaft
InventorsRichard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
Claims12
A method for treating a disease-state in a human patient, wherein the disease-state is associated with expression of an RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2, which method comprises administering to the patient a therapeutically effective amount of an antibody or a fragment thereof, wherein
- (i) the isolated antibody or a fragment thereof comprises
- a) a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 26 or SEQ ID NO:
- 29, or
- b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 30, or SEQ ID NO:
- 31 or
- c) a light chain variable region having the amino acid sequence of SEQ ID NO:
- 26 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 27 or SEQ ID NO:
- 28, or
- d) a light chain variable region having the amino acid sequence of SEQ ID NO:
- 29 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 30 or SEQ ID NO:
- 31,
- thereby treating the disease-state in the human patient.
A method for treating a disease-state in a human patient, wherein the disease-state is associated with expression of an RQl polypeptide having the amino acid sequence of SEQ ID NO:
- 2, which method comprises administering to the patient a therapeutically effective amount of an antibody or a fragment thereof, wherein
- (i) the isolated antibody or a fragment thereof comprises:
- a) a light chain CDR3 sequence comprising the amino acid residues 110 to 117 of SEQ ID NO:
- 26,
- b) a heavy chain CDR3 sequence comprising the amino acid residues 117 to 132 of SEQ ID NO:
- 27,
- c) a light chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 44 to 55 of SEQ ID NO:
- 26 and 71 to 77 of SEQ ID NO:
- 26, respectively, and
- d) a heavy chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 50 to 54 of SEQ ID NO:
- 27 and 69 to 84 of SEQ ID NO:
- 27, respectively,
- thereby treating the disease-state in the human patient.
A method for treating a disease-state in a human patient, wherein the disease-state is associated with expression of an RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2, which method comprises administering to the patient a therapeutically effective amount of an antibody or a fragment thereof, wherein
- (i) the isolated antibody or a fragment thereof comprises:
- a) a light chain CDR3 sequence comprising the amino acid residues 110 to 117 of SEQ ID NO:
- 29,
- b) a heavy chain CDR3 sequence comprising the amino acid residues 117 to 126 of SEQ ID NO:
- 30,
- c) a light chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 44 to 55 of SEQ ID NO:
- 29 and 71 to 77 of SEQ ID NO:
- 29, respectively, and
- d) a heavy chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 50 to 54 of SEQ ID NO:
- 30 and 69 to 84 of SEQ ID NO:
- 30, respectively,
- thereby treating the disease-state in the human patient.
Dependencies are inferred from the claim text.